Study #2025-0078
A phase 1/2, multicenter, open-label study to evaluate the safety, tolerability, and preliminary antitumor activity of TNG456 monotherapy and in combination with Abemaciclib in patients with solid tumors with MTAP loss
MD Anderson Study Status
Enrolling
Treatment Agent
TNG456, abemaciclib
Description
This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. The study drug, TNG456, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 191 participants.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor, Non-Small Cell Adenocarcinoma, Lung Cancer, Brain Tumor
Study phase:
Physician name:
Jordi Rodon Ahnert
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.